Introduction
The relationship between human papillomavirus (HPV) infection and both cervical cancer and its precursor, cervical intraepithelial neoplasia (CIN), in women is now well established [1] . The association between HIV infection and HPV-related lesions, initially suggested by a higher prevalence of cervical lesions in HIVinfected than in uninfected women [2±5], was con-®rmed in other studies in which confounding factors (e.g. sexual behaviour and HPV infection) were controlled for [6±8] . The prevalence and the severity of cervical lesions have been reported to increase with increasing HIV-induced immunode®ciency [4,6±11] . A few prospective studies have also shown that cervical lesions are more likely to occur, progress, and recur after treatment in HIV-infected than in HIV-negative women [8,12±14] . Speci®c guidelines for the management of gynaecological diseases among HIV-infected women are needed. Whereas there appears to be a general consensus that HIV-infected women with a still-preserved immune function should be treated in the same way as HIV-uninfected women, the management of cervical lesions in severely immunocompromised HIV-infected women remains controversial.
Improving the diagnosis and clinical management of HPV-related cervical lesions in HIV-infected women requires that the natural history of HPV infection in these women be better understood. To assess the impact of immunode®ciency and of antiretroviral therapy on the occurrence and evolution of cervical lesions, data from a European cohort of HIV-infected women were analysed.
Methods

Study population
The European cohort on natural history of HIV infection in women is a prospective cohort of HIVinfected women with a known date of infection. Enrolment required that the date of HIV infection could be estimated within at most a 2-year time frame, either by a negative followed by a positive HIV test, or by a limited period of HIV risk behaviour, irrespective of the delay between infection and enrolment. Between May 1993 and April 1998, 485 women who gave informed consent were enrolled from 23 centres in 12 countries: Belgium, Denmark, Finland, France, Greece, Italy, Netherlands, Norway, Portugal, Spain, Sweden and Switzerland. In 21 centres, follow-up was performed every 6 months and is still ongoing.
Data collected
At each visit, women were interviewed about their socio-demographic characteristics, sexual behaviour and gynaecological and obstetric history using standardized questionnaires; HIV-related data (CD4 cell count, antiretroviral treatment, clinical stage [15] ) were collected and a gynaecological examination including Papanicolaou (Pap) test was performed. No guidelines were given to the participating physicians regarding the management of abnormal Pap tests. All Pap smear slides were read in a single laboratory (Pasteur-Cerba, Cergy-Pontoise, France). Using the Bethesda classi®cation, cervical cell abnormalities were classi®ed either as atypical squamous or glandular cells of undetermined signi®cance (ASCUS or AGCUS), or as low-or highgrade squamous intraepithelial lesions (SIL) [16] . Data on colposcopic examination and on biopsy results (if any) were collected. Histological lesions were classi®ed as CIN I, II or III according to the Richart classi®cation [17] .
At enrolment, cervical samples for HPV detection were collected by brushing and placed in cryotubes containing Minimum Eagle's Medium and antibiotics at À808C. DNA was extracted and quanti®ed. HPV was detected using the Southern blot (SB) technique with hybridization using three different cocktails, each containing three radioactive probes to identify mildly oncogenic (HPV 6, 11 and 42), moderately oncogenic (HPV 31, 35 and 39) and highly oncogenic (HPV 16, 18 and 33) types [18] . The analysis of the restriction patterns obtained after washing the blots at low and high stringency allowed detection of all HPV types with high-level homology to the nine probes used as well as those with partial homology. As SB is not very sensitive in detecting HPV [19] , a second test was performed using PCR. HPV DNA was ampli®ed using the`consensus' primers of Manos [20] . Hybridization of the PCR product with a cocktail of probes was used to speci®cally identify HPV 16, 18, and 33, and another cocktail of`consensus' probes (GP1, GP2 [20] ) was used to detect all other HPV types.
Data analysis
The prevalence of SIL on the ®rst interpretable Pap test (initial Pap test) was calculated and studied according to HPV detection, adequacy of the Pap tests for diagnostic evaluation, clinical and biological stage of HIV infection, antiretroviral therapy, gynaecological and obstetrical history and socio-demographic characteristics. The incidence of SIL was estimated in women with normal initial Pap tests using the Kaplan±Meier method. For both analyses, Pap smears with ASCUS or AGCUS evoking a reactive process were considered as normal; those with ASCUS evoking SIL were counted as SIL.
Progression and regression rates from untreated lowgrade SIL were estimated using the Kaplan±Meier method in women with low-grade SIL detected at enrolment or during follow-up. Progression was as-sumed when high-grade SIL was detected on a subsequent Pap test. Regression was de®ned by a normal Pap smear, if the following smear was also normal. For women for whom no further Pap test was available after a single normal smear, follow-up was censored at the visit preceding the single normal smear. Women treated for cervical lesions were censored at the time of treatment.
For all analyses, Pap tests for which no cervical squamous cell could be observed, for whatever reason (e.g. obscuring in¯ammation), were considered as uninterpretable. Results of HPV detection by SB were grouped into: (i) 16, 18, 33 (HPV types`16, 18, 33' and related types); (ii)`31, 35, 39' (types 31, 35, 39 and related types); or (iii)`6, 11, 42' (types 6, 11, 42, related and undetermined types). When several types were detected by SB, results were classi®ed according to the most oncogenic type. A woman was considered as receiving antiretroviral treatment at a given visit if the treatment had been prescribed at least 1 month prior to the visit. Adequacy of the Pap tests was de®ned by the presence of an endocervical/transformation zone component.
Differences in proportions, means and medians were tested using respectively the Pearson ÷ 2 (or Fisher's exact test where appropriate), Student's t and Kruskal± Wallis tests. Differences in incidence or regression rates were tested using the log-rank test. Stepwise multiple logistic regression models were used to identify factors independently associated with prevalent SIL. Multivariate analyses of factors associated with incident SIL or with regression from low-grade SIL were performed using Cox regression models. The Kaplan±Meier and the multivariate analyses were performed using BMDP software (University of California Press, Berkeley, California, USA). A signi®cance level of 0.05 was chosen and adjusted odds ratios (aOR) or relative risks (aRR) were computed with 95% con®dence intervals (CI).
Results
Study population
The study population comprised 467 women with at least one interpretable Pap test. Population characteristics are presented in Table 1 . In the 21 centres participating in follow-up, 423 women were included, among whom 310 were followed-up at least once and contributed to the follow-up analysis with a median time of 2 years (25 th percentile, 1 year; 75 th percentile, 2.5 years).
The proportion of women followed-up was 66.4% (310/467) and differed signi®cantly according to the type of recruitment site (53.6% in STD clinics, 61.5% in infectious disease clinics, 72.9% in drug treatment centres, 78.4% in gynaecological clinics; P , 0.01) and according to the region of enrolment (51.1% in southern Europe, 82.7% in middle Europe, 80.6% in Nordic countries; P , 0.001). No difference in the proportion of women followed-up was observed according to age at enrolment, region of birth, HIV-related data (CD4 cell count, clinical stage, HIV transmission group, time between infection and enrolment) or results of the Pap test and of HPV detection performed at enrolment.
Prevalence of and risk factors for SIL
SIL was detected on the initial Pap test in 24.2% (113/ 467) of the women (low-grade, 98; high-grade, 13; ASCUS evoking SIL, two). SIL detection differed signi®cantly according to HPV detection, CD4 cell count, age, presence of genital warts, past history of genital warts, previous pregnancy, history of SIL and type of recruitment site ( In multivariate analysis, six factors were found to be independently associated with a higher prevalence of Table 2) . Similar results were found when the analysis was restricted to the 310 women followed-up at least once (data not shown).
The magnitude of the association between HPV detection by SB and prevalent SIL increased with decreasing CD4 cell count, although the interaction was not statistically signi®cant: the aOR associated with a positive detection by SB ranged from 5.6 (95% CI, 1.4± 21.7) for CD4 cell counts . 500 3 10 6 /l to 10.6 (3.7± 30.2) for CD4 counts of 200±499 3 10 6 /l and 17.9 (4.0±79.7) for CD4 counts , 200 3 10 6 /l. The aOR associated with a positive detection by PCR only remained unchanged regardless of the immunode®ciency level.
Incidence of and risk factors for SIL
Among the 317 women who were enrolled in the 21 centres with follow-up and whose initial Pap test was normal, 229 were followed-up for a median time of 2 years (range, 6 months to 4 years). SIL was diagnosed in 70 women (low-grade, 61; high-grade, six; ASCUS evoking SIL, three). The cumulative incidence of SIL was estimated to be 23.6% at 1 year and 29.5% at 18 months (27.7% and 2.5% at 18 months for low-and high-grade SIL respectively). As the incidence of SIL in the 101 women with no history of SIL and whose last normal Pap test had been performed within the year preceding enrolment did not differ from that in other women (27.0% versus 31.8% at 18 months; P 0.36) data from both groups were analysed together.
The incidence of SIL was signi®cantly higher in HPVpositive than in HPV-negative women (P , 0.001) ( Table 3) . It tended to increase with decreasing CD4 cell count at the time of the initial normal Pap test (P 0.16). It was signi®cantly higher in women who had genital warts at the initial visit than in other women (P 0.01). Higher incidences were observed in women with past SIL, young women and women recruited in Nordic countries than in other women, but none of the differences was statistically signi®cant (respectively P 0.12, 0.22 and 0.78).
Using a Cox regression model, HPV detection and CD4 cell count were independently associated with incident SIL. Compared with HPV-negative women, the risk of developing SIL was increased in SB-positive women and in women positive for HPV types 16, 18, Strati®ed by CD4 count, women on antiretroviral therapy at initial normal Pap test tended to have a lower incidence of SIL (17.5% and 28.0% at 1 year for CD4 cell counts of 200±499 3 10 6 /l and , 200 3 10 6 /l respectively) than untreated women (26.1% and 42.3% respectively) (P 0.44). Among the 68 treated women with CD4 counts ,500 3 10 6 /l, 41 were treated with a single nucleoside analogue (mainly zidovudine) and 27 with a drug combination (including a protease inhibitor for seven women). These numbers were too small to study the incidence of SIL according to the type of antiretroviral therapy. All but one of the 68 women were still receiving antiretroviral therapy at the end of follow-up. After adjustment for HPV detection (Cox regression model), the risk of developing SIL was higher in women not receiving than in women receiving antiretroviral therapy: the increase in SIL incidence associated with CD4 cell counts , 500 3 10 6 /l versus . 500 3 10 6 /l was signi®cant in untreated women [aRR, 1.9 (95% CI, 1.0±3.6) and 2.9 (1.1±8.0) for CD4 counts of 200±499 3 10 6 /l and , 200 3 10 6 /l respectively], whereas it was less marked and not statistically signi®cant in treated women [aRR, 1.3 (0.6±2.8) and 1.7 (0.8±3.5) respectively].
Evolution of low-grade SIL
Among the 165 women diagnosed with low-grade SIL, 40 had no subsequent Pap test and 10 were immediately treated for SIL/CIN. For the remaining 115 women, the median time of follow-up in absence of treatment for SIL/CIN was 18 months (range, 6 months to 3.5 years).
Only 11 women progressed to high-grade SIL and regression was observed in 33 women. The cumulative rates of progression and of regression at 1 year were 8.1% and 29.5% respectively. Both rates remained unchanged (8.3% and 30.9%) when women who underwent a biopsy were censored at the time of biopsy. Regression rates were higher in HPV-negative than in other women (P 0.18) and decreased with increasing immunode®ciency (P 0.12) ( Table 4 ). They ranged from 77.8% at 1 year in eight HPVnegative women with CD4 cell counts . 500 3 10 6 /l to 0% at 1 year in 11 women SB-positive for HPV`16, 18, 33' with CD4 cell counts , 200 3 10 6 /l. Among women with CD4 cell counts , 500 3 10 6 /l, the cumulative rates of regression at 1 year were 20.5% in those receiving antiretroviral therapy at low-grade SIL diagnosis and 31.4% in untreated women (P 0.30), but the median CD4 cell count was lower in treated (218 3 10 6 /l) than in untreated women (348 3 10 6 /l) (P , 0.01).
After adjustment for HPV detection (Cox regression model), a decreasing trend in the probability of regression was found with decreasing CD4 cell count but was not statistically signi®cant: compared with CD4 cell counts . 500 3 10 6 /l, the aRR associated with CD4 cell counts , 200 3 10 6 /l was 0.5 (95% CI, 0.2±1.4).
Biopsy results and treatment for CIN
A cervical biopsy was performed in 22 of the 30 women diagnosed with high-grade SIL. Biopsy con-®rmed high-grade CIN in 15 women (68%) (CIN II, nine; CIN III, six), revealed CIN I in four and was CIN-negative in three. Treatment for CIN was performed in all women with high-grade CIN and in three women with CIN I or CIN-negative biopsy. In two of these three women, the colposcopy showed acetowhite lesions; in the third woman, the squamouscolumnar junction was not visible. Among the four women with CIN I or CIN-negative biopsy who were not treated, two had a normal colposcopic examination, one had signs of chronic cervicitis, and one had acetowhite lesions. Among the 18 women treated for CIN, one (with CIN I at biopsy) was treated by cryotherapy, 15 by excisional procedures (loop electrosurgical excision or conization) and two by hysterectomy. The histological results of surgical specimens were available for 14 women: high-grade CIN was con®rmed in 13 (CIN II, six; CIN III, seven) and CIN I was diagnosed in one woman (who had CIN II at biopsy).
A biopsy was performed in 58 of the 165 women with low-grade SIL. Normal results were found in 20 women, CIN I was diagnosed in 21 and high-grade CIN in 17 (CIN II, 10; CIN III, seven). Among the 15 biopsies performed after a single smear with lowgrade SIL, 33.3% showed high-grade CIN and 40.0% were CIN-negative; these proportions were respectively 27.9% and 32.6% among the 43 biopsies performed for persistent low-grade SIL. Eleven women with high-grade CIN were treated: eight by excisional procedures and three by destructive treatments (cryotherapy or laser vaporization).
Recurrence or persistence of SIL after treatment for high-grade CIN was assessed in 21 women in whom a subsequent Pap test was performed (within 2±15 months of treatment). The proportion of persistent/ recurrent SIL was 50% in 12 women treated for CIN II and 67% in nine treated for CIN III. None of the four women with more than 500 3 10 6 CD4 cells/l at the time of CIN treatment, six of the 11 with 200± 499 3 10 6 CD4 cells/l and all six with , 200 3 10 6 CD4 cells/l had persistent/recurrent SIL. The median CD4 cell count was lower in women with persistent/ recurrent SIL than in others (196 3 10 6 /l and 411 3 10 6 /l respectively, P 0.02).
Discussion
This study is one of the largest to evaluate the incidence of SIL in HIV-infected women. Our ®ndings, obtained through a 2-year median follow-up of 229 women, clearly support an increase in SIL incidence with increasing HIV-related immunode®ciency.
In the only published prospective study in which SIL incidence could be estimated according to the severity of HIV-related immunode®ciency, the cumulative rates in 160 women followed-up for 13 months ranged from 17% in both women receiving antiretroviral therapy and untreated women with CD4 cell counts . 500 3 10 6 /l to 27% in untreated women with CD4 cell counts , 500 3 10 6 /l [8] . In our study, although the difference was not statistically signi®cant, incidence rates were lower in women receiving antiretroviral therapy at the time of initial normal Pap test than in untreated women with the same levels of immunode®ciency. However, compared with women with a stillpreserved immune function, a signi®cant increase in the risk of developing SIL was found in immunode®cient women who were not receiving antiretroviral therapy, whereas no signi®cant increase was observed in treated women. This result may suggest a protective effect of antiretroviral therapy against the occurrence of SIL in HIV-infected women. However, the speci®c effect of antiretroviral therapy cannot be disentangled from a more general effect of regular medical care prior to enrolment (which was not measured in our study). Furthermore, in our study, few women have been followed-up beyond mid-1996, when highly active antiretroviral therapy (HAART) and HIV viral load measurement became available. The in¯uence of viral load lowering due to antiretroviral therapy on the occurrence of SIL could not therefore be assessed.
The association between prevalent SIL and HIV-related immunode®ciency has been reported previously [6±9]. The protective role of the integrity of the immune system against HPV-related lesions was ®rst suggested by studies showing an increased risk of such lesions in women receiving immunosuppressive treatments [21, 22] . However, the mechanism through which HIV-related immunode®ciency increases the risk of SIL/CIN is not well understood. In the present study, the association between HIV-related immunode®ciency and prevalent or incident SIL remained statistically signi®cant after controlling for HPV detection. This association may be interpreted as a promoting effect of immunode®ciency on the carcinogenic effect of HPV. By decreasing the immune control of HPV infection, immunode®ciency may increase the duration of HPV infection or may allow HPV to replicate to higher levels, thus increasing the risk of oncogenic progression. As SB is less sensitive than PCR in detecting HPV [19] , detection by SB should correspond to a higher HPV load in the cervix than detection by PCR only. Because HPV detection by SB and by PCR only was controlled for, differences in HPV load were partly taken into account. The increase in the risk of SIL associated with a positive SB detection according to the severity of immunode®ciency may therefore be explained by a higher HPV load in highly immunocompromised women.
Regression at 1 year from untreated low-grade SIL was observed in only 30% of the women. A similar regression rate was found when women who underwent a biopsy were censored at the time of biopsy, suggesting that the spontaneous evolution of low-grade SIL was not altered by biopsies. In order to reduce the false-negative rate, regression was de®ned by two consecutive normal smears. The rate of regression may therefore have been underestimated. However, the estimated rate is similar to those reported among HIVinfected women in two studies [8, 23] . In another study in which immunocompromised HIV-infected women were examined prior to and after initiation of HAART, a higher regression rate (43%) was observed [24] . Although much greater than in these three studies, the relatively small size of the present study sample (115 women) makes it dif®cult to identify factors associated with regression from low-grade SIL. Nevertheless, a decreasing trend in regression rates was observed with decreasing CD4 cell count. The rate estimated in women with CD4 cell counts . 500 3 10 6 /l (46% at 1 year) is consistent with that of 62% observed in 555 HIV-negative immunocompetent women followed-up for 4 years [25] .
The response to treatment for high-grade CIN was associated with the level of immunocompetence, with rates consistent with other studies. In women with severe HIV-related immunode®ciency, persistence or recurrence of CIN is very common and high recurrence/persistence rates (. 60%) were reported in all previously published studies [13, 14] . In contrast, in immunocompetent HIV-negative women, treatment for CIN is usually successful, with cure rates . 90% [26] . Compared with HIV-negative women, more extensive CIN which are more likely to involve the endocervical canal were reported in HIV-infected women [27] . As the study questionnaire did not include speci®c data on histology of surgical specimen margins, persistent CIN due to residual CIN after treatment could not be distinguished from recurrent CIN.
Although in HIV-infected women, the sensitivity of Pap smear, compared with cervical biopsy, was questioned in one study [28] , subsequent reports have shown high sensitivity (ranging from 63% to 94%) and positive predictive value (from 64% to 94%), similar to those observed in HIV-uninfected women [6, 29, 30] .
Biopsy is recommended only in cases of persistent low-grade SIL; for evident ethical reasons, no further guidelines regarding the diagnostic con®rmation of CIN were given for the purpose of this study. Among women with low-grade SIL, although very few had a biopsy, the proportion with high-grade CIN was high (29%), whether the biopsy was done following one or more than one smear showing low-grade SIL. Moreover, the proportion of CIN-negative biopsies remained as high (34%) among biopsies performed for persistent low-grade SIL as among those done after a single smear with low-grade SIL. This suggests that the proportion of CIN-negative biopsies among smears with low-grade SIL was overestimated in our study, probably because some lesions were missed at biopsy. For high-grade SIL, concordance with results of biopsy or of surgical specimen examination was quite satisfactory. It is therefore unlikely that the true rate of high-grade CIN was overestimated with Pap tests.
Whereas the risk of prevalent SIL was increased in women with untreated SIL within the year preceding enrolment in the cohort, no signi®cant association was found with treated SIL within the year of enrolment or with earlier SIL. However, the history of abnormal Pap tests was not estimated accurately as the data were collected retrospectively. The decreasing trend in SIL prevalence with increasing age is consistent with that observed in the general population in the USA [31] . As genital warts are related to HPV types which are rarely associated with genital cancer [18] , the association between SIL and genital warts may result from infections with multiple HPV types (including multiple oncogenic types). The association with the region of enrolment is dif®cult to interpret and may be due to confounding factors not taken into account in our study.
The detection of SIL was not associated with sexual behaviour or with contraceptive history, although these factors have been shown to be associated with cervical cancer in HIV-uninfected women [32] . However, our study population comprised only HIV-infected women, most of them infected through heterosexual intercourse or through injecting drug use, and its relative homogeneity regarding risk factors for cervical cancer may have precluded the ability to detect associations of these factors with SIL.
Despite high incidence of CIN and progression to higher grade CIN in immunocompromised women, no invasive cervical cancer was diagnosed. The follow-up may not have been long enough for cancer to occur. Furthermore, the incidence of cervical cancer may have been underestimated as treatment for CIN was not performed systematically using excisional procedures and as, for obvious ethical reasons, biopsy was not performed at each visit. In addition, timely treatment of SIL/CIN may have prevented the progression of these lesions to cancer.
In HIV-infected women, severe immunode®ciency is associated with a high prevalence of SIL, a high incidence of SIL, a low regression rate from low-grade SIL, and a high rate of recurrence or persistence after treatment for high-grade CIN. In women with severe immunode®ciency, preventing CIN from progressing without repeated excisional treatment, which could result in cervical stenosis, may require an optimization of the immune function which should be obtainable by HAART.
